NCT02428036View on ClinicalTrials.gov

A Study of TBI-1401(HF10) in Patients With Solid Tumors With Superficial Lesions

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

October 31, 2016

Study Completion Date

June 30, 2017

Conditions
Solid Tumor
Interventions
BIOLOGICAL

TBI-1401(HF10)

Patients will receive intratumoral administrations of TBI-1401(HF10). The dose is 1 mL of 1x10\^6 TCID50/mL.

BIOLOGICAL

TBI-1401(HF10)

Patients will receive intratumoral administrations of TBI-1401(HF10). The dose is 1 mL of 1x10\^7 TCID50/mL.

Trial Locations (1)

104-0045

National Cancer Center Hospital, Chuo-ku

All Listed Sponsors
lead

Takara Bio Inc.

INDUSTRY

NCT02428036 - A Study of TBI-1401(HF10) in Patients With Solid Tumors With Superficial Lesions | Biotech Hunter | Biotech Hunter